Evotec AG of Germany has spun out a drug discovery company called Topas Therapeutics GmbH. It is being launched with a €14m series A financing round led by VC firm Epidarex Capital, of which Eli Lilly is an investor. The round also included EMBL Ventures, Gimv and Evotec.
Evotec AG of Germany has spun out a drug discovery company called Topas Therapeutics GmbH. It is being launched with a €14m series A financing round led by VC firm Epidarex Capital, of which Eli Lilly is an investor. The round also included EMBL Ventures, Gimv and Evotec.
Topas has been built around technology licensed from the University Medical Center Hamburg-Eppendorf where it was invented by Dr Johannes...
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
The osteogenesis imperfecta drug stumbled in a second interim analysis.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
